Profound Medical (PROF) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Profound Medical

NasdaqCM•Healthcare•Medical Devices

$6.89+0.09(0.01%)Market closed

Market Cap

$211.92M

P/S

11.1x

P/B

4.3x

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

How this company scores

AverageMetricSide Score: 43/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Cash & Earnings Quality (6/25).

Profitability6/25

Growth10/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality6/25

Strengths

Low leverageImproving leverageConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 11.1x5y range 7.4x – 14.0x

Currently near its 4-quarter median.

P/B · 4.3x5y range 2.9x – 4.8x

Currently near its 7-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 7 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $211.92M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $19.09M
Q. Revenue: $2.48M
TTM EBITDA: $-34.88M
TTM Op. Income: $-35.37M
Q. Op. Income: $-11.07M
TTM Net Income: $-32.74M
Q. Net Income: $-9.54M
EPS: $-0.26
Shares Out.: $36.35M

$19.09M in TTM revenue grew from zero YoY, reaching $2.48M last quarter. TTM EBITDA of $-34.88M and TTM operating income of $-35.37M show growth is flowing through to the bottom line. However, net income is negative at $32.74M — growth is not yet reaching the bottom line. Across the last 7 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 78.4%
EBITDA Margin: -440.2%
Op. Margin: -445.7%
Net Margin: -384.2%

Op. margin of -445.7% is up 178.8% YoY — cost efficiency is improving. Net margin at -384.2% and gross margin of 78.4% show how much of each revenue dollar survives to profit. Across the last 7 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 11.1x
P/B Ratio: 4.3x

P/S of 11.1x and P/B of 4.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $62.38M
Cash: $38.27M
Long-Term Debt: $4.51M
Book Value: $49.81M
D/E Ratio: 0.1
Debt/EBITDA: N/A

With $62.38M in assets and $4.51M in long-term debt, D/E is 0.1and book value is $49.81M — a conservative capital structure with a cushion to weather downturns. Across the last 7 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-11.34M
TTM Free Cash Flow: $-36.28M
FCF Margin: -190.1%
FCF / Net Income: 1.1

TTM FCF of $-36.28M on $-11.34M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — an improving trend.